Trial Profile

Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 28 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Valbenazine (Primary)
Indications Chorea; Huntington's disease
Focus Adverse reactions; Registrational
Acronyms KINECT-HD2
Sponsors Neurocrine Biosciences

Most Recent Events

07 Nov 2024 Results presented in the Neurocrine Biosciences Media Release.
30 Sep 2024 According to a Neurocrine Biosciences media release, interim data from the study were Presented at the 2024 MDS International Congress of Parkinson's Disease and Movement Disorders
30 Sep 2024 Interim Results presented in the Neurocrine Biosciences Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com